Genelux Corporation—a privately-held, clinical-stage biopharmaceutical company headquartered in San Diego—and are doing a clinical study treating canine cancer patients with V-VET1, an investigational veterinary-use vaccinia virus cancer treatment.
The investigational treatment has been shown to attack cancer tumors without harming healthy tissues, and may spare canine patients the negative side effects of conventional therapies like chemo and radiation.
These trials can offer treatment for owners who might not otherwise be able to help or afford such treatment for their pets.
According to estimates by the Comparative Oncology Program at the Center for Cancer Research of the National Cancer Institute, there are roughly six million new cancer diagnoses in dogs each year.
Experts estimate that almost 50 percent of all dogs over the age of 10 will develop cancer and approximately one in four of all dogs will at some stage in their life develop a cancer.
For more information on the cancer trials you can visit CVS Angel Care Cancer Center in Carlsbad at 2310 Faraday Ave., call (760) 431-2273 or email email@example.com.